SPL currently has a market capitalisation of ~$380m
Payments for AZD0466 could be “up to $2.5b” according to JF
Can anyone see where AZ could save about $2b in development costs? Anyone?
One thing JF stated (and I would need to check the presentation again to be sure) was that future drugs to be DEP'd may not even require phase 2 trials. If this is anything more than wishful thinking on JF's part then it would open the floodgates to future revenue streams.
Webinar this Friday 8th April with Jackie Fairley, page-50
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.003(3.00%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.7¢ | $38.11K | 389.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20455 | 9.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 38876 | 3 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |